Falling EBITDA, persistent market pressure, high capex, weak segment growth and NBR's dependence on asset sales pose risks to its long-term stability.
J&J faces Stelara losses, Medicare shifts, talc suits and China pressure, banking on new products and expects segment growth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback